Brief: U.S. FDA Grants Orphan Drug Designation To Gamgertamig For The Treatment Of Pemphigus
24/08/2026 21:12
BRIEF-U.S. FDA Grants Orphan Drug Designation To Gamgertamig For The Treatment Of Pemphigus Aug 24 (Reuters) - Lakefront Biotherapeutics NV LKFT.AS:
U.S. FDA GRANTS ORPHAN DRUG DESIGNATION TO GAMGERTAMIG FOR THE TREATMENT OF PEMPHIGUS
LAKEFRONT BIOTHERAPEUTICS NV - GAMGERTAMIG IN PHASE 2 STUDIES; REGISTRATION STUDIES EXPECTED IN 2027
Source text: ID:nGNX34NSWf
Further company coverage: LKFT.AS
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Lakefront Biotherapeutics NV
See all newsBrief: Lakefront Announces Sale Of Preclinical Car-T Programs To Armed Cell Therapeutics
RBC upgrades Lakefront Biotherapeutics to 'outperform' on gamgertamig prospect
Brief: U.S. FDA Grants Orphan Drug Designation To Gamgertamig For The Treatment Of Pemphigus
Brief: Lakefront Biotherapeutics H1 Net Profit From Continuing Operations €15.8 Mln
Brief: Gilead Sciences and Lakefront Complete Acquisition of Ouro Medicines to Further Expand Inflammation Pipeline